These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26701750)

  • 1. Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.
    Freitas EO; Nico D; Alves-Silva MV; Morrot A; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004297. PubMed ID: 26701750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8
    Rodrigues LS; Barreto AS; Bomfim LGS; Gomes MC; Ferreira NLC; da Cruz GS; Magalhães LS; de Jesus AR; Palatnik-de-Sousa CB; Corrêa CB; de Almeida RP
    Front Immunol; 2021; 12():773983. PubMed ID: 34777391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
    Duarte MC; Lage LM; Lage DP; Martins VT; Carvalho AM; Roatt BM; Menezes-Souza D; Tavares CA; Alves RJ; Barichello JM; Coelho EA
    Parasitol Int; 2016 Dec; 65(6 Pt A):728-736. PubMed ID: 27425599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.
    Kaur T; Makkar P; Randhawa K; Kaur S
    Parasitol Res; 2013 Jan; 112(1):91-100. PubMed ID: 22961311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with a CD4
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
    Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
    Front Immunol; 2018; 9():967. PubMed ID: 29867949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.
    Islamuddin M; Chouhan G; Want MY; Ozbak HA; Hemeg HA; Afrin F
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005011. PubMed ID: 27776125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The F1F3 Recombinant Chimera of
    Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB
    Front Immunol; 2019; 10():724. PubMed ID: 31024556
    [No Abstract]   [Full Text] [Related]  

  • 10. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
    Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis.
    Sharma M; Sehgal R; Kaur S
    PLoS Negl Trop Dis; 2012; 6(5):e1629. PubMed ID: 22563510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection.
    Tavares GSV; Mendonça DVC; Miyazaki CK; Lage DP; Soyer TG; Carvalho LM; Ottoni FM; Dias DS; Ribeiro PAF; Antinarelli LMR; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
    Parasitol Int; 2019 Feb; 68(1):63-72. PubMed ID: 30339837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    de Franca MNF; Rodrigues LS; Barreto AS; da Cruz GS; Aragão-Santos JC; da Silva AM; de Jesus AR; Palatnik-de-Sousa CB; de Almeida RP; Corrêa CB
    Front Immunol; 2024; 15():1277557. PubMed ID: 38410517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
    Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
    Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters.
    Pereira L; Abbehusen M; Teixeira C; Cunha J; Nascimento IP; Fukutani K; dos-Santos W; Barral A; de Oliveira CI; Barral-Netto M; Soto M; Brodskyn CI
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003490. PubMed ID: 25642946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.
    Alexander J; Carter KC; Al-Fasi N; Satoskar A; Brombacher F
    Eur J Immunol; 2000 Oct; 30(10):2935-43. PubMed ID: 11069076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis.
    Islamuddin M; Chouhan G; Farooque A; Dwarakanath BS; Sahal D; Afrin F
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e3321. PubMed ID: 25568967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
    Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
    Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.